Developer docs
API playgroundTry for free, no card

Search company profiles

Japan BCG Laboratory

Full company profile

uuid00247pe

Namestring
Japan BCG Laboratory
Legal namestring
日本ビーシージー製造株式会社
Websiteurl
bcg.gr.jp
Company typeenum
Private
Founded yearint
1952
Descriptiontext

Japan BCG Laboratory (日本ビーシージー製造株式会社) is a Tokyo-based, privately held pharmaceutical manufacturer founded in 1952 as a spin-off from the Japan Anti-Tuberculosis Association's production division. The company is the sole supplier of BCG vaccine in Japan and has manufactured more than 2.25 billion doses over six decades, exporting to over 50 countries under WHO prequalification granted in 1987. Its core technology is freeze-drying (lyophilization) of BCG vaccine using the proprietary Tokyo-172 strain — originally brought to Japan from the Pasteur Institute in 1924 and selected by WHO as the 1st Reference Reagent in 2009. The product portfolio spans freeze-dried BCG vaccines (percutaneous and intradermal formulations), purified tuberculin PPD for TB infection diagnosis, Immunobladder intravesical solution for bladder cancer (distribution transferred to Nippon Kayaku in 2013), FTA-ABS syphilis diagnostics, HISCL immunoassay reagents for Sysmex analyzers, and point-of-care tests including VeritFast H-FABP, VeritFast PCT, and IMM-FASTCHECK HIT-IgG.

The company operates a sales-led GTM primarily through direct supply to healthcare institutions and Japanese municipal governments for the national immunization program, with international export for global TB prevention and a dedicated Customer Center handling product inquiries. Its wholly owned subsidiary Japan Lyophilization Laboratory (日本凍結乾燥研究所), established in 1961 and restructured through the 2012 merger with Yurin Tokushu Kogyo, handles in vitro diagnostics and medical device manufacturing under ISO 13485:2016 certification. Recent strategic activity centers on a May 2026 exclusive U.S. Development and Supply Agreement with ImmunityBio for the Tokyo-172 BCG strain in non-muscle invasive bladder cancer treatment, addressing the chronic U.S. BCG shortage and signaling international commercial expansion of the company's biological assets beyond infectious disease prevention. The company holds no parent ownership and no evidence of external institutional investors, with ownership and operational control resting under President Seiichi Inoue.

Short descriptiontext

Japan BCG Laboratory is a privately held, Tokyo-based pharmaceutical manufacturer founded in 1952 and the sole supplier of BCG vaccine in Japan. It produces freeze-dried BCG vaccines using the proprietary Tokyo-172 strain, tuberculin PPD diagnostics, and a portfolio of in vitro and point-of-care diagnostic reagents for domestic immunization programs and export to 50+ countries.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
BCG vaccine manufacturing, tuberculosis prevention, in vitro diagnostics, pharmaceutical manufacturing, freeze-dried vaccines
Industry3 codes
PRIMARYHLAIAEAE
Travel & Tropical Disease Vaccines
SECONDARYBPADAIAB
Immunization & Vaccine Delivery Programs
SECONDARYHLAIAEAN
Vaccine Procurement, Tendering & Immunization Supply Programs
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
BCG Vaccine Manufacturing and Diagnostics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1BCG Vaccine Sales
TypeOne Time License
Description

Sales of freeze-dried BCG vaccines for tuberculosis prevention to healthcare institutions, municipal governments, and for export to international markets. The company supplies over 2.25 billion doses globally over more than 60 years.

bcg.gr.jp
2Diagnostic Product Sales
TypeOne Time License
Description

Sales of in vitro diagnostic products including purified tuberculin PPD, FTA-ABS test kits, HISCL reagents, and POCT reagents (H-FABP, PCT) to medical laboratories and healthcare facilities.

bcg.gr.jp
3Immunobladder Sales
TypeOne Time License
Description

Sales of Immunobladder intravesical product for bladder cancer treatment, which was transferred to Nippon Kayaku Co., Ltd. for distribution from July 2013.

bcg.gr.jp
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Technology or R&D, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Japan BCG Laboratory is the sole Japanese manufacturer of BCG vaccines for tuberculosis prevention, producing freeze-dried BCG vaccines (intradermal and percutaneous formulations) using the proprietary Tokyo-172 strain. The company also manufactures purified tuberculin PPD for TB infection diagnosis, the Immunobladder intravesical BCG product for bladder cancer treatment, and in vitro diagnostic reagents including the FTA-ABS syphilis test kit, HISCL automated immunoassay reagents, and point-of-care tests for cardiac and thrombocytopenia markers. Products are supplied to Japan's national immunization program, hospitals, clinics, and exported to over 50 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • More than 2.25 billion doses of BCG vaccine supplied globally
+2 more records
Product overview1 text field

Japan BCG Laboratory is Japan's sole BCG vaccine manufacturer, producing a portfolio of vaccines, tuberculin diagnostics, and in vitro diagnostic reagents. Core products include the Tokyo 172 strain freeze-dried BCG vaccines for tuberculosis prevention (available in percutaneous and intradermal formulations), purified tuberculin PPD for infection testing, and Immunobladder for bladder cancer treatment. The company also manufactures a comprehensive range of diagnostic reagents including the FTA-ABS test for syphilis, HISCL automated immunoassay reagents for Sysmex instruments (covering hepatitis, tumor markers), and point-of-care tests (VeritFast H-FABP, VeritFast PCT, IMM-FASTCHECK HIT-IgG) for cardiac markers and thrombocytopenia screening. Associated company Japan Lyophilization Laboratory handles in vitro diagnostics and medical devices.

Product and service12 records
1Freeze-dried BCG Vaccine for Percutaneous Use (乾燥BCGワクチン(経皮用・1人用))
CategoryVaccines (BCG)
Description

Freeze-dried BCG vaccine for percutaneous use via multi-puncture device for tuberculosis prevention. Contains the Tokyo-172 BCG strain. Pack of 1 dose with diluent. Used by healthcare institutions for routine infant BCG vaccination under Japan's national immunization program and exported internationally.

2Freeze-dried BCG Vaccine for Intradermal Use (乾燥BCGワクチン(皮内用))
CategoryVaccines (BCG)
Description

Freeze-dried BCG vaccine for intradermal injection for tuberculosis prevention. Each ampoule contains 0.5 mg BCG (70% water content) plus 1.0 mL diluent, supplied in packs of 100 ampoules. Used for BCG vaccination by healthcare institutions and exported for international TB prevention programs.

3Purified Tuberculin PPD (一般診断用精製ツベルクリン(PPD)1人用)
CategoryIn vitro diagnostics (tuberculin)
Description

Purified Protein Derivative (PPD) tuberculin for intradermal Mantoux test for tuberculosis infection diagnosis. Each vial contains 1 µg PPD (equivalent to 50 tuberculin units). Used by hospitals, clinics, and medical laboratories for TB screening.

4Immunobladder Intravesical (イムノブラダー膀注用)
CategoryBCG immunotherapy (bladder cancer)
Description

BCG intravesical solution for treatment of TaT1 papillary tumors and carcinoma in situ (CIS) of the urinary bladder. Contains 80 mg BCG (70% water content) per vial. Used in oncology treatment for bladder cancer immunotherapy. Now sold and distributed by Nippon Kayaku Co., Ltd.

5FTA-ABS Test SG-KIT (トレポネーマ抗体检出用 FTA-ABSテスト-SG-KIT(KW))
CategoryIn vitro diagnostics (infectious disease)
Description

Indirect fluorescent antibody absorption test kit for detecting Treponema pallidum antibodies in serum for syphilis diagnosis. Uses Nichol's antigen slides in packs of 100 tests. Japan's only diagnostic reagent for this immunostaining procedure.

6HISCL Immunoassay Reagents (HISCL™専用試薬)
CategoryIn vitro diagnostics (automated immunoassay)
Description

Reagent series for Sysmex HISCL fully automated immunoassay system. Includes TPAb, HBsAb, HBeAg, HBeAb, HBcAb, HBcAbII, CA15-3, and HBcIgM assay kits. Features 17-minute reaction time and 10-30 µL sample volume. Used by medical laboratories for hepatitis, syphilis, and cancer marker testing.

7VeritFast H-FABP (ヴェリファスト H-FABP)
CategoryPoint-of-care diagnostics (cardiac markers)
Description

Point-of-care immuno-chromatographic test kit for detecting human heart-type fatty acid-binding protein (H-FABP) in plasma, serum, or whole blood, with a measurement time of 10 minutes. Used for early acute myocardial infarction diagnosis.

8VeritFast PCT (ヴェリファスト PCT)
CategoryPoint-of-care diagnostics (infection markers)
Description

Point-of-care immuno-chromatographic test kit for measuring procalcitonin (PCT) in plasma, serum, or whole blood. Used for sepsis and bacterial infection diagnostics.

9IMM-FASTCHECK HIT-IgG (イムファストチェック HIT-IgG)
CategoryPoint-of-care diagnostics (hematology)
Description

Immuno-chromatographic test kit for detecting anti-platelet factor 4/heparin complex IgG antibodies (HIT antibodies), used for heparin-induced thrombocytopenia diagnosis. Measurement time: 15 minutes, with 3 tests per pack.

10CC-E Nichibi Pre-treatment Solution (抗酸菌検出用前処理液 CC-E ニチビー)
CategoryMycobacteria detection reagents
Description

Pre-treatment solution containing 2% sodium hydroxide for sputum liquefaction with NALC (N-acetyl-L-cysteine) for decontamination, used with phosphate buffer for mycobacterial culture. A subsidiary (Japan Lyophilization Laboratory) diagnostic reagent.

11Phosphate Buffer Nichibi (抗酸菌検出用緩衝液 リン酸緩衝液 ニチビー)
CategoryMycobacteria detection reagents
Description

Phosphate buffer solution (pH 6.8) for mycobacteria detection. Used for dilution and neutralization of alkali-treated specimens before mycobacterial culture. A subsidiary (Japan Lyophilization Laboratory) diagnostic reagent.

12Disposable Multi-Puncture Device for BCG Vaccination (ディスポBCG接種用管針)
CategoryMedical device (vaccination)
Description

Disposable multi-puncture device for BCG vaccination. Used with the percutaneous BCG vaccine for tuberculosis prevention vaccination procedures. A medical device product of Japan Lyophilization Laboratory.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-16
Description

ImmunityBio signed an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory to develop, import, and commercialize the Tokyo-172 BCG strain for treating high-grade non-muscle invasive bladder cancer. The agreement is supported by positive Phase III data from the NCI-sponsored SWOG S1602 trial demonstrating non-inferiority of Tokyo-172 BCG compared to TICE BCG. ImmunityBio plans to engage with the FDA for regulatory pathway to approval, providing a second potential BCG source to address the over-decade-long chronic BCG shortage in the United States.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Japan BCG Laboratory's partner ImmunityBio has an existing partnership with the Serum Institute of India for recombinant BCG, which serves as an additional potential BCG source for addressing the U.S. BCG shortage alongside the Japan BCG Laboratory Tokyo-172 strain agreement.

3公益財団法人結核予防会 (Japan Anti-Tuberculosis Association)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Japan BCG Laboratory was originally established in 1952 as a spin-off from the Japan Anti-Tuberculosis Association's (公益財団法人結核予防会) manufacturing division. The company continues to collaborate with the association on tuberculosis prevention efforts and uses reference materials and expertise developed through this historical relationship.

bcg.gr.jp
4株式会社日本凍結乾燥研究所 (Japan Lyophilization Laboratory)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Japan Lyophilization Laboratory is a subsidiary of Japan BCG Laboratory, established in 1961 to apply the company's freeze-drying technology to diagnostic agents and other products. The subsidiary merged with Yurin Tokushu Kogyo K.K. in 2012 and now focuses on in vitro diagnostics and medical devices. It manufactures diagnostic reagents for Sysmex HISCL automated immunoassay systems and other products.

bcg.gr.jp
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Japan BCG Laboratory

BCG Vaccine Manufacturing and Diagnosticsbcg.gr.jp

Japan BCG Laboratory is a privately held, Tokyo-based pharmaceutical manufacturer founded in 1952 and the sole supplier of BCG vaccine in Japan. It produces freeze-dried BCG vaccines using the proprietary Tokyo-172 strain, tuberculin PPD diagnostics, and a portfolio of in vitro and point-of-care diagnostic reagents for domestic immunization programs and export to 50+ countries.

What Japan BCG Laboratory does

Japan BCG Laboratory (日本ビーシージー製造株式会社) is a Tokyo-based, privately held pharmaceutical manufacturer founded in 1952 as a spin-off from the Japan Anti-Tuberculosis Association's production division. The company is the sole supplier of BCG vaccine in Japan and has manufactured more than 2.25 billion doses over six decades, exporting to over 50 countries under WHO prequalification granted in 1987. Its core technology is freeze-drying (lyophilization) of BCG vaccine using the proprietary Tokyo-172 strain — originally brought to Japan from the Pasteur Institute in 1924 and selected by WHO as the 1st Reference Reagent in 2009. The product portfolio spans freeze-dried BCG vaccines (percutaneous and intradermal formulations), purified tuberculin PPD for TB infection diagnosis, Immunobladder intravesical solution for bladder cancer (distribution transferred to Nippon Kayaku in 2013), FTA-ABS syphilis diagnostics, HISCL immunoassay reagents for Sysmex analyzers, and point-of-care tests including VeritFast H-FABP, VeritFast PCT, and IMM-FASTCHECK HIT-IgG.

The company operates a sales-led GTM primarily through direct supply to healthcare institutions and Japanese municipal governments for the national immunization program, with international export for global TB prevention and a dedicated Customer Center handling product inquiries. Its wholly owned subsidiary Japan Lyophilization Laboratory (日本凍結乾燥研究所), established in 1961 and restructured through the 2012 merger with Yurin Tokushu Kogyo, handles in vitro diagnostics and medical device manufacturing under ISO 13485:2016 certification. Recent strategic activity centers on a May 2026 exclusive U.S. Development and Supply Agreement with ImmunityBio for the Tokyo-172 BCG strain in non-muscle invasive bladder cancer treatment, addressing the chronic U.S. BCG shortage and signaling international commercial expansion of the company's biological assets beyond infectious disease prevention. The company holds no parent ownership and no evidence of external institutional investors, with ownership and operational control resting under President Seiichi Inoue.

Japan BCG Laboratory firmographics

Firmographics
Name
Japan BCG Laboratory
Legal name
日本ビーシージー製造株式会社
Website
https://bcg.gr.jp
Company type
Private
Founded year
1952
Operating status
Operating
Short description
Japan BCG Laboratory is a privately held, Tokyo-based pharmaceutical manufacturer founded in 1952 and the sole supplier of BCG vaccine in Japan. It produces freeze-dried BCG vaccines using the proprietary Tokyo-172 strain, tuberculin PPD diagnostics, and a portfolio of in vitro and point-of-care diagnostic reagents for domestic immunization programs and export to 50+ countries.
Ownership category
akta.pro rank

Japan BCG Laboratory industry classification

Industry
Product category
BCG Vaccine Manufacturing and Diagnostics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIAEAE
Travel & Tropical Disease Vaccines
SECONDARYBPADAIAB
Immunization & Vaccine Delivery Programs
SECONDARYHLAIAEAN
Vaccine Procurement, Tendering & Immunization Supply Programs

Keywords

  • BCG vaccine manufacturing
  • Tuberculosis prevention
  • In vitro diagnostics
  • Pharmaceutical manufacturing
  • Freeze-dried vaccines

Where Japan BCG Laboratory is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices2 records

Markets served

Japan BCG Laboratory business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Supply Chain, Infrastructure

Revenue model

  1. BCG Vaccine Sales: Sales of freeze-dried BCG vaccines for tuberculosis prevention to healthcare institutions, municipal governments, and for export to international markets. The company supplies over 2.25 billion doses globally over more than 60 years.
  2. Diagnostic Product Sales: Sales of in vitro diagnostic products including purified tuberculin PPD, FTA-ABS test kits, HISCL reagents, and POCT reagents (H-FABP, PCT) to medical laboratories and healthcare facilities.
  3. Immunobladder Sales: Sales of Immunobladder intravesical product for bladder cancer treatment, which was transferred to Nippon Kayaku Co., Ltd. for distribution from July 2013.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Japan BCG Laboratory product offering

Product offering

Core offering

Japan BCG Laboratory is the sole Japanese manufacturer of BCG vaccines for tuberculosis prevention, producing freeze-dried BCG vaccines (intradermal and percutaneous formulations) using the proprietary Tokyo-172 strain. The company also manufactures purified tuberculin PPD for TB infection diagnosis, the Immunobladder intravesical BCG product for bladder cancer treatment, and in vitro diagnostic reagents including the FTA-ABS syphilis test kit, HISCL automated immunoassay reagents, and point-of-care tests for cardiac and thrombocytopenia markers. Products are supplied to Japan's national immunization program, hospitals, clinics, and exported to over 50 countries.

Product overview

Japan BCG Laboratory is Japan's sole BCG vaccine manufacturer, producing a portfolio of vaccines, tuberculin diagnostics, and in vitro diagnostic reagents. Core products include the Tokyo 172 strain freeze-dried BCG vaccines for tuberculosis prevention (available in percutaneous and intradermal formulations), purified tuberculin PPD for infection testing, and Immunobladder for bladder cancer treatment. The company also manufactures a comprehensive range of diagnostic reagents including the FTA-ABS test for syphilis, HISCL automated immunoassay reagents for Sysmex instruments (covering hepatitis, tumor markers), and point-of-care tests (VeritFast H-FABP, VeritFast PCT, IMM-FASTCHECK HIT-IgG) for cardiac markers and thrombocytopenia screening. Associated company Japan Lyophilization Laboratory handles in vitro diagnostics and medical devices.

Differentiator

Problem solved

Functional benefit

Products and services

  • Freeze-dried BCG Vaccine for Percutaneous Use (乾燥BCGワクチン(経皮用・1人用)) Freeze-dried BCG vaccine for percutaneous use via multi-puncture device for tuberculosis prevention. Contains the Tokyo-172 BCG strain. Pack of 1 dose with diluent. Used by healthcare institutions for routine infant BCG vaccination under Japan's national immunization program and exported internationally.
  • Freeze-dried BCG Vaccine for Intradermal Use (乾燥BCGワクチン(皮内用)) Freeze-dried BCG vaccine for intradermal injection for tuberculosis prevention. Each ampoule contains 0.5 mg BCG (70% water content) plus 1.0 mL diluent, supplied in packs of 100 ampoules. Used for BCG vaccination by healthcare institutions and exported for international TB prevention programs.
  • Purified Tuberculin PPD (一般診断用精製ツベルクリン(PPD)1人用) Purified Protein Derivative (PPD) tuberculin for intradermal Mantoux test for tuberculosis infection diagnosis. Each vial contains 1 µg PPD (equivalent to 50 tuberculin units). Used by hospitals, clinics, and medical laboratories for TB screening.
  • Immunobladder Intravesical (イムノブラダー膀注用) BCG intravesical solution for treatment of TaT1 papillary tumors and carcinoma in situ (CIS) of the urinary bladder. Contains 80 mg BCG (70% water content) per vial. Used in oncology treatment for bladder cancer immunotherapy. Now sold and distributed by Nippon Kayaku Co., Ltd.
  • FTA-ABS Test SG-KIT (トレポネーマ抗体检出用 FTA-ABSテスト-SG-KIT(KW)) Indirect fluorescent antibody absorption test kit for detecting Treponema pallidum antibodies in serum for syphilis diagnosis. Uses Nichol's antigen slides in packs of 100 tests. Japan's only diagnostic reagent for this immunostaining procedure.
  • HISCL Immunoassay Reagents (HISCL™専用試薬) Reagent series for Sysmex HISCL fully automated immunoassay system. Includes TPAb, HBsAb, HBeAg, HBeAb, HBcAb, HBcAbII, CA15-3, and HBcIgM assay kits. Features 17-minute reaction time and 10-30 µL sample volume. Used by medical laboratories for hepatitis, syphilis, and cancer marker testing.
  • VeritFast H-FABP (ヴェリファスト H-FABP) Point-of-care immuno-chromatographic test kit for detecting human heart-type fatty acid-binding protein (H-FABP) in plasma, serum, or whole blood, with a measurement time of 10 minutes. Used for early acute myocardial infarction diagnosis.
  • VeritFast PCT (ヴェリファスト PCT) Point-of-care immuno-chromatographic test kit for measuring procalcitonin (PCT) in plasma, serum, or whole blood. Used for sepsis and bacterial infection diagnostics.
  • IMM-FASTCHECK HIT-IgG (イムファストチェック HIT-IgG) Immuno-chromatographic test kit for detecting anti-platelet factor 4/heparin complex IgG antibodies (HIT antibodies), used for heparin-induced thrombocytopenia diagnosis. Measurement time: 15 minutes, with 3 tests per pack.
  • CC-E Nichibi Pre-treatment Solution (抗酸菌検出用前処理液 CC-E ニチビー) Pre-treatment solution containing 2% sodium hydroxide for sputum liquefaction with NALC (N-acetyl-L-cysteine) for decontamination, used with phosphate buffer for mycobacterial culture. A subsidiary (Japan Lyophilization Laboratory) diagnostic reagent.
  • Phosphate Buffer Nichibi (抗酸菌検出用緩衝液 リン酸緩衝液 ニチビー) Phosphate buffer solution (pH 6.8) for mycobacteria detection. Used for dilution and neutralization of alkali-treated specimens before mycobacterial culture. A subsidiary (Japan Lyophilization Laboratory) diagnostic reagent.
  • Disposable Multi-Puncture Device for BCG Vaccination (ディスポBCG接種用管針) Disposable multi-puncture device for BCG vaccination. Used with the percutaneous BCG vaccine for tuberculosis prevention vaccination procedures. A medical device product of Japan Lyophilization Laboratory.

Quantifiable outcome

  • More than 2.25 billion doses of BCG vaccine supplied globally
  • +2 more outcomes

Companies that use Japan BCG Laboratory

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Japan BCG Laboratory technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Japan BCG Laboratory partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • ImmunityBiocoreStrategic or Co-development Partner · 16 May 2026ImmunityBio signed an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory to develop, import, and commercialize the Tokyo-172 BCG strain for treating high-grade non-muscle invasive bladder cancer. The agreement is supported by positive Phase III data from the NCI-sponsored SWOG S1602 trial demonstrating non-inferiority of Tokyo-172 BCG compared to TICE BCG. ImmunityBio plans to engage with the FDA for regulatory pathway to approval, providing a second potential BCG source to address the over-decade-long chronic BCG shortage in the United States.
  • Serum Institute of IndiaminorStrategic or Co-development PartnerJapan BCG Laboratory's partner ImmunityBio has an existing partnership with the Serum Institute of India for recombinant BCG, which serves as an additional potential BCG source for addressing the U.S. BCG shortage alongside the Japan BCG Laboratory Tokyo-172 strain agreement.
  • 公益財団法人結核予防会 (Japan Anti-Tuberculosis Association)coreStrategic or Co-development PartnerJapan BCG Laboratory was originally established in 1952 as a spin-off from the Japan Anti-Tuberculosis Association's (公益財団法人結核予防会) manufacturing division. The company continues to collaborate with the association on tuberculosis prevention efforts and uses reference materials and expertise developed through this historical relationship.
  • 株式会社日本凍結乾燥研究所 (Japan Lyophilization Laboratory)coreStrategic or Co-development PartnerJapan Lyophilization Laboratory is a subsidiary of Japan BCG Laboratory, established in 1961 to apply the company's freeze-drying technology to diagnostic agents and other products. The subsidiary merged with Yurin Tokushu Kogyo K.K. in 2012 and now focuses on in vitro diagnostics and medical devices. It manufactures diagnostic reagents for Sysmex HISCL automated immunoassay systems and other products.

Scale indicators4 records

Recent moves10 records

Expansion highlights4 records

Japan BCG Laboratory competitors and assessment

Company assessment

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Japan BCG Laboratory compliance and trust

Trust signal

Compliance1 record

Japan BCG Laboratory financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Japan BCG Laboratory leadership team

Management profile

Number of profiles

Profiles9 records

Japan BCG Laboratory subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Japan BCG Laboratory funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Japan BCG Laboratory M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Japan BCG Laboratory

What does Japan BCG Laboratory do?

Japan BCG Laboratory is the sole Japanese manufacturer of BCG vaccines for tuberculosis prevention, producing freeze-dried BCG vaccines (intradermal and percutaneous formulations) using the proprietary Tokyo-172 strain. The company also manufactures purified tuberculin PPD for TB infection diagnosis, the Immunobladder intravesical BCG product for bladder cancer treatment, and in vitro diagnostic reagents including the FTA-ABS syphilis test kit, HISCL automated immunoassay reagents, and point-of-care tests for cardiac and thrombocytopenia markers. Products are supplied to Japan's national immunization program, hospitals, clinics, and exported to over 50 countries.

Is Japan BCG Laboratory a public or private company?

Japan BCG Laboratory is a private company. It is classified as management employee owned and is currently operating.

When was Japan BCG Laboratory founded?

Japan BCG Laboratory was founded in 1952.

Where is Japan BCG Laboratory based?

Japan BCG Laboratory is headquartered in Tokyo, Japan, in the Asia region.

How does Japan BCG Laboratory make money?

Three revenue lines are on record. BCG Vaccine Sales are the primary driver. The others are diagnostic Product Sales and immunobladder Sales.

Does Japan BCG Laboratory have an API?

No public API is recorded for Japan BCG Laboratory.

What industry is Japan BCG Laboratory in?

Japan BCG Laboratory's product category is BCG Vaccine Manufacturing and Diagnostics. Its primary akta.pro industry code is HLAIAEAE, Travel & Tropical Disease Vaccines, with a secondary code of BPADAIAB, Immunization & Vaccine Delivery Programs. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 MillionImmunityBio reported Q2 2026 net product revenue of $50.7 million, up 92% year-over-year and 15% sequentially, with first-half revenue of $94.8 million, up 121% year-over-year. The company also advanced regulatory and clinical programs, including an FDA sBLA review for ANKTIVA plus BCG and an exclusive agreement with Japan BCG Laboratory.LA Business JournalFDA to Review Expanded Use of Cancer DrugImmunityBio's FDA application for expanded use of Anktiva in bladder cancer was accepted for review, with a decision deadline of Jan. 6. The company also acquired a BCG strain from Japan BCG Laboratory for an undisclosed sum, gaining exclusive U.S. rights to develop and commercialize it.StocktwitsIBRX Stock Rises Overnight: Investors Eye FDA Workshop On Anktiva After Exclusive Japan BCG DealImmunityBio, Inc. (IBRX) stock climbed 2% in overnight trading as investors await a pivotal FDA workshop on Monday regarding the company's pending filing to expand Anktiva's use in bladder cancer treatment, specifically addressing whether carcinoma in situ (CIS) and papillary bladder cancer constitute the same disease. The company simultaneously announced an exclusive U.S. agreement with Japan BCG Laboratory for the Tokyo-172 BCG strain, providing a second supply source to address the long-standing BCG shortage in the U.S. Founder Patrick Soon-Shiong also outlined broader "Immunotherapy 2.0" ambitions combining IL-15, NK cells, and AI-driven technology across NantWorks companies.BioSpaceImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035ImmunityBio announced five issued U.S. patents covering its ANKTIVA plus BCG combination for non-muscle invasive bladder cancer, with terms extending through at least 2035. The patents protect the approved product, dosing regimen, and two-vial kit, supporting its commercial franchise and pending BLA.Business Wire BlogImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035ImmunityBio announced five issued U.S. patents covering its ANKTIVA plus BCG combination for non-muscle invasive bladder cancer, with terms extending through at least 2035. The patents protect the approved product, dosing regimen, and two-vial kit, supporting its BCG-unresponsive NMIBC franchise and pending regulatory approvals.BioSpaceImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United StatesImmunityBio signed an exclusive U.S. agreement with Japan BCG Laboratory to develop, import, and commercialize the Tokyo strain of BCG for bladder cancer. The Tokyo strain showed non-inferior efficacy to TICE BCG in the SWOG S1602 trial, and ImmunityBio plans to engage the FDA to address the U.S. BCG shortage.AijournImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United StatesImmunityBio announced an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory (JBL) to develop, import, and commercialize the Tokyo strain of BCG (Tokyo-172 BCG) for bladder cancer treatment in the United States. The agreement is supported by positive Phase III results from the NCI-sponsored SWOG S1602 trial, which demonstrated non-inferiority of the Tokyo strain versus TICE BCG in BCG-naïve high-grade non-muscle invasive bladder cancer patients. ImmunityBio plans to serve as the sole U.S. Biologics License Application applicant and engage with the FDA to address the over decade-long BCG shortage in the United States.Business Wire BlogImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United StatesImmunityBio signed an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory, gaining exclusive rights to develop, import, and commercialize the Tokyo-172 BCG strain for bladder cancer treatment. The agreement is supported by positive Phase III data from the NCI-sponsored SWOG S1602 trial, which demonstrated non-inferiority of the Tokyo strain versus TICE BCG in BCG-naïve high-grade non-muscle invasive bladder cancer. The company plans to engage with the FDA to pursue U.S. approval, positioning this as a second potential BCG source to address the more than decade-long BCG shortage in the United States.